Summary
Vertex Pharmaceuticals Inc. (VRTX) filed an 8-K on January 26, 2022, to announce its financial results for the fourth quarter and full year ended December 31, 2021. The filing incorporates by reference a press release issued on January 26, 2022, which details these results. Investors should refer to the attached press release (Exhibit 99.1) for the specific financial performance, operational updates, and forward-looking statements from Vertex during that period.
Key Highlights
- 1Vertex Pharmaceuticals filed an 8-K on January 26, 2022.
- 2The filing pertains to the company's financial results for the fourth quarter and full year ended December 31, 2021.
- 3The press release containing the financial results is attached as Exhibit 99.1.
- 4The press release is incorporated by reference into the 8-K filing.
- 5Information in the press release is furnished, not filed, under Section 18 of the Securities Exchange Act of 1934, limiting its liability implications.
- 6The filing also includes the Cover Page Interactive Data File in XBRL format.
Frequently Asked Questions
The detailed financial results for the fourth quarter and full year ended December 31, 2021, are provided in the press release dated January 26, 2022, which is attached as Exhibit 99.1 to this 8-K filing and incorporated by reference.
Information that is 'furnished' under Item 2.02 is generally not subject to the same level of liability under Section 18 of the Securities Exchange Act of 1934 as information that is 'filed'. This means that while the information is publicly disclosed, the company faces less risk of legal action if there are inaccuracies in the furnished information, provided they are not intentionally misleading.
This 8-K primarily serves to report historical financial results. Any strategic updates, operational highlights, or future guidance would be detailed within the accompanying press release (Exhibit 99.1) which investors should review.